Doug Hampton

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand USA – English USA – English

by

MUMBAI, India and SIENA, Italy, May 30, 2023 /PRNewswire/ — Sun Pharmaceutical Industries Limited (Reuters: SUN.BO), (Bloomberg: SUNP IN), (NSE: SUNPHARMA), (BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Philogen S.p.A (BIT: PHIL) today announced that they have entered into a licensing agreement for commercializing Philogen’s specialty product, Nidlegy™ (Daromun) in … Read more

“There has never been a trial” … Didier Raoult denies having conducted “the largest wild therapeutic trial known to date”

by

the essential After 16 learned medical societies qualified Didier Raoult’s latest report on hydroxychloroquine as “the largest known ‘wild’ therapeutic trial”, the former boss of the Marseille IHU defended himself on Tuesday, May 30 . He evokes him an “observational study”, which has nothing to do with a test. Sixteen learned medical societies challenged the … Read more

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline

by

Strengthening of strategic option license agreement to cover additional novel ADC targets COPENHAGEN, Denmark, May 30, 2023 /PRNewswire/ — Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, announced the expansion of its current collaboration with Duality Biologics (“Duality”), … Read more

Medivir to present at the ABGSC Life Science Summit

by

STOCKHOLM, May 30, 2023 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the ABGSC Life Science Summit today May 30, 2023. CEO Jens Lindberg will present the company and its plan for … Read more

Tidetron se distingue au Future Food Asia 2023, et remporte le prix de la startup de biotechnologie agroalimentaire à la croissance la plus rapide en Chine USA – Français USA – English APAC – English USA – español

by

SINGAPOUR, 30 mai 2023 /PRNewswire/ — La 7e édition du Future Food Asia (FFA) s’est terminée en mai, avec un triomphe retentissant pour Tidetron Bioworks Technology Co., Ltd. La performance exceptionnelle de l’entreprise dans l’industrie de la biotechnologie agroalimentaire lui a valu le titre convoité de la « Startup de biotechnologie agroalimentaire à la croissance la … Read more

Tidetron brilla en Future Food Asia 2023

by

– Tidetron brilla en Future Food Asia 2023, obteniendo el premio a la empresa emergente de biotecnología agroalimentaria de más rápido crecimiento en China SINGAPUR, 30 de mayo, 2023 /PRNewswire/ — La séptima edición de la conferencia Future Food Asia (FFA) concluyó en mayo y culminó con un rotundo triunfo para Tidetron Bioworks Technology Co., Ltd. … Read more

Se otorga la cuarta aprobación de EDI a Concept Medical para el balón recubierto de sirolimus MagicTouch, que trata la enfermedad de la arteria femoral superficial (AFS) Latin America – español USA – English USA – English USA – español USA – Deutsch Middle East – Arabic

by

TAMPA, Florida, 30 de mayo de 2023 /PRNewswire/ — La FDA de los Estados Unidos otorgó el 24 de mayo de 2023 una aprobación de exención de dispositivo en investigación (EDI) para el balón recubierto de sirolimus (SCB) MagicTouch PTA de Concept Medical Inc para el tratamiento de la enfermedad de la arteria femoral superficial (SFA). … Read more

A quarta aprovação de IDE da Concept Medical para o Balão Revestido com Sirolimus MagicTouch é concedida para o tratamento da Doença da Artéria Femoral Superficial (SFA) USA – English USA – English Middle East – English India – English España – español Deutschland – Deutsch Middle East – Arabic Latin America – español Brazil – Português

by

TAMPA, Flórida, 30 de maio de 2023 /PRNewswire/ — A FDA dos EUA, em 24 de maio de 2023, concedeu uma aprovação de Isenção de Dispositivo Investigacional (IDE) para o Balão Revestido de Sirolimus (SCB) MagicTouch PTA da Concept Medical Inc para o tratamento de Artérias Femorais Superficiais (SFA). Isso marca a quarta aprovação da IDE … Read more

Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease

by

LUND, Sweden, May 30, 2023 /PRNewswire/ — Hansa Biopharma (“Hansa”), a pioneer in enzyme technology for rare immunological conditions, today announced the first patient has been dosed with imlifidase in the GOOD-IDES-02 trial, a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Søren Tulstrup, President and CEO, Hansa Biopharma said, “This is … Read more